Accelerating Life-Saving Therapies: Waters Corporation Revolutionizes Bioprocessing
Waters Corporation, a pioneer in high-performance liquid chromatography, has made a groundbreaking announcement in the life sciences sector. The company has unveiled BioResolve Protein A Affinity Columns, a game-changing innovation that promises to accelerate the development of lifesaving therapies.
The new columns are designed to streamline upstream bioprocessing, allowing researchers to access results earlier and faster. This breakthrough is particularly significant in downstream development for biologics, where method optimization is a critical step. By introducing BioResolve Protein A Affinity Columns, Waters is empowering scientists to work more efficiently, reducing the time and resources required to develop antibody-based drug products.
The impact of this innovation is substantial. With the new columns, researchers can now measure antibody titers up to 2 days earlier, and enjoy up to 7x improvements in sensitivity thanks to novel high efficiency particles. This means that scientists can refine their processes, identify potential issues earlier on, and make data-driven decisions to optimize their workflows.
The implications of this development are far-reaching. By addressing a major bottleneck in the development of biotherapeutics like monoclonal antibodies, Waters is helping to bring lifesaving therapies to patients faster. This is a significant step forward in the fight against diseases, and a testament to the company’s commitment to innovation and customer satisfaction.
Key Benefits of BioResolve Protein A Affinity Columns:
- Earlier access to results in upstream bioprocessing
- Faster method optimization in downstream development for biologics
- Improved process agility in the discovery, optimization, and manufacturing of antibody-based drug products
- Precise titer measurements, enabling up to 2 days earlier measurements for antibody titers
- Up to 7x improvements in sensitivity with novel high efficiency particles